ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that ARUP's Tanya Sandrock received a prestigious National Institutes of Health (NIH) grant to research additional HIV therapies.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company, today announced that it plans to present at the Rodman and Renshaw Annual Global Investment Conference in New York on Friday, September 11, 2009.
Rigaku Americas Corporation is pleased to announce that the company has entered into an agreement with TTP LabTech to offer the mosquito nanolitre pipetting system as part of the Rigaku CrystalMation platform for automated protein crystallization experiments.
Vitex Systems, Inc., a leading technology developer, licensor and engineering service provider for thin-film encapsulation and moisture barrier films, today announced that it has executed a license agreement with a global supplier of specialty materials and related thin-film services, granting them the rights to develop and manufacture Vitex's proprietary Barix Barrier Film.
mPhase Technologies, Inc. will be exhibiting recent advancements made in the development of its Smart NanoBattery technology this week at the NanoBusiness 2009 Conference at McCormick Place in Chicago, IL.
Integran Technologies Inc. today announced that it has entered into a Market Development Agreement with Magnetic Shield Corporation to accelerate market penetration of Integran's Nanovate EM coating for low frequency magnetic shielding.
Novaled AG, a leader in energy saving and long living OLEDs (Organic Light Emitting Diodes), and Plextronics, Inc., an international company that specializes in conductive organic inks for printed lighting, solar and other electronics, announced today that they have agreed to jointly develop doped and solution processed organic materials for OLED applications.
NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns.